Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b…
Global Filmmakers Are Leveraging Kling AI to Push the Boundaries of Storytelling, Cannes Panel Presents
Cannes, France, May 20, 2026 (GLOBE NEWSWIRE) -- A shift is underway…
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to…
ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026
– Complete response (CR) observed in 70% (50/72) of evaluable patients with…
Imviva Biotech Presents Data Demonstrating Durable Clinical Responses from Ongoing Phase 1/2 Study of CTA313 in Systemic Lupus Erythematosus at ASGCT 2026
100% of patients treated with CTA313 achieved an SRI-4 response, with half…
Linglong Tire Presents Sustainable Concept Tire at World Business Council for Sustainable Development
MONTREUX, Switzerland, May 7, 2026 /PRNewswire/ -- From April 27-28, 2026, the…
Making Waves Across Borders: Manipal Hospitals Presents the First-Ever Sri Lanka-India Open Water Swim by a Couple
BENGALURU, India, May 4, 2026 /PRNewswire/ -- Manipal Hospitals, India's largest pan-India multispecialty…
Berlin Heals Presents Positive Late Breaking Results from the CMIC-III First-In-Human Less Invasive Study
High Impact Session presented at Heart Rhythm Society's Congress in ChicagoFirst time…
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability…
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
April 19, 2026 19:45 ET | Source: Sutro Biopharma, Inc. STRO-004 demonstrates…
